Cystic Fibrosis Modulator Therapy

Trikafta. Jillian Curran, via Wikimedia Commons.

The development of cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs, most recently elexacaftor/tezacaftor/ivacaftor (ETI), has transformed the treatment of patients with cystic fibrosis. A new study from researchers at Nationwide Children’s Hospital shows that ETI therapy has the potential to change even the lives of patients with advanced lung disease.

Read the whole story here: Modulator Therapy Improves Lives of Patients with Cystic Fibrosis with Severe Lung Disease.